China’s market jitters clip biopharma shares

Concerns that biopharma could become the next industry to be scrutinized by Beijing sent shares falling in Hong Kong and New York Monday after a government directive related to the education sector has decreed that academic tutoring companies can no longer be publicly traded. Two investors who spoke to BioCentury and remain upbeat on China biotech explain what’s behind the sector’s latest roller-coaster ride.

Three ETFs focused on tracking Chinese biopharmas — the China BioPharma ETF (NASDAQ:CHNA), Global X MSCI China Health Care ETF, KraneShares MSCI All China Health Care Index ETF— were each down 7% compared with a 4% dip for the Hang Seng Index...